CorMedix Inc.(NYSEMKT:CRMD): Lost Pace On The Stock Market


Dallas, Texas 01/23/2014 (FINANCIALSTRENDS) – CorMedix Inc.(NYSEMKT:CRMD) has lost pace on the stock market in the second week of January, recording slide of 12% as did many other companies in the same market segment.

CorMedix Inc.(NYSEMKT:CRMD) has thus far had a successful run based on the high performance of some of its innovative product range. These which include the likes of Catheter lock such as the Neutrolin, which is popular in the prevention of infections in the bloodstream of patients. The company has since been providing this in the German as well as Austrian market spaces. The company hopes that the catheter lock, for which it has received the CE Mark will also be extended for the product in the US as well.

CorMedix Inc.(NYSEMKT:CRMD) has been working on a strategy to enter the competitive US medical and accented medical care products segment. The company hopes that the innovative catheter lock would be approved by the regulatory bodies of the country, allowing growth in market base for the company, besides an alternative option for patients. Innovation in therapeutics has been CorMedix by-line and company has been persistent in providing variety and diversified medical products which offer quicker, safer and more cost effective medical care.

CorMedix Inc.(NYSEMKT:CRMD) is a $41.46million market cap company with volume of 338,367. The company has recorded $2.90 52 week low and $0.48. The company currently has an EPS of -0.55.

CorMedix Inc.(NYSEMKT:CRMD) is a United States based drug manufacturer, which engaged in development stage pharmaceuticals as well as medical device manufacturing. The company also uses in-licenses to develop as well as commercial some of the products as well as treatments which are already available for such fatal conditions as heart attacks or cardiac arrests. The company is also known to offer products which are helpful in the better management of renal failure or when the kidney fails to perform at required levels.